Hideaki Sowa Selected Research

blosozumab

9/2015	The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
2/2015	A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideaki Sowa Research Topics

Disease

17	Osteoporosis 10/2015 - 04/2002
3	Bone Resorption 02/2015 - 01/2002
3	Hypercalcemia (Milk Alkali Syndrome) 01/2015 - 01/2002
3	Primary Hyperparathyroidism 03/2004 - 10/2003
2	Metabolic Bone Diseases (Osteopenia) 09/2015 - 02/2015
2	Pain (Aches) 01/2015 - 11/2012
2	Postmenopausal Osteoporosis 01/2015 - 11/2012
2	Neoplasms (Cancer) 10/2003 - 04/2003
1	Injection Site Reaction 02/2015
1	Chondrocalcinosis (Pseudogout) 01/2015
1	Calcium Metabolism Disorders 01/2015
1	Periarthritis 01/2015
1	Stroke (Strokes) 01/2014
1	Body Weight (Weight, Body) 05/2012
1	Nausea 06/2011
1	Diabetes Mellitus 06/2011
1	Hypoglycemia (Reactive Hypoglycemia) 06/2011
1	Acquired Immunodeficiency Syndrome (AIDS) 04/2011
1	Type 2 Diabetes Mellitus (MODY) 01/2009
1	Insulin Resistance 08/2007
1	Glucose Intolerance 08/2007
1	Obesity 08/2007
1	Coffin-Lowry Syndrome (Syndrome, Coffin-Lowry) 12/2006
1	Carcinogenesis 03/2004
1	Secondary Hyperparathyroidism 03/2004
1	Multiple Endocrine Neoplasia Type 1 03/2004
1	Hypercalciuria 04/2003
1	Hypophosphatemia 04/2003
1	Cysts 04/2003
1	Atherosclerosis 04/2002
1	Hepatocellular Carcinoma (Hepatoma) 02/2002
1	Multiple Myeloma 01/2002
1	Humoral Hypercalcemia Of Malignancy 01/2002

Drug/Important Bio-Agent (IBA)

8	Teriparatide (Parathar)FDA Link 01/2015 - 01/2011
5	Raloxifene Hydrochloride (Evista)FDA Link 10/2015 - 11/2012
3	Biomarkers (Surrogate Marker)IBA 02/2015 - 04/2011
3	CalciumIBA 01/2015 - 04/2003
2	blosozumabIBA 09/2015 - 02/2015
2	Vitamin D FDA LinkGeneric 01/2015 - 03/2013
2	Exenatide (Byetta)FDA Link 06/2011 - 01/2009
2	BiguanidesIBA 06/2011 - 01/2009
2	2,4-thiazolidinedione (thiazolidinedione)IBA 06/2011 - 01/2009
2	GlucocorticoidsIBA 04/2005 - 01/2005
2	Parathyroid Hormone (Parathormone)IBA 03/2004 - 04/2003
1	Monoclonal AntibodiesIBA 02/2015
1	Cholecalciferol (Vitamin D3)FDA Link 01/2015
1	diphosphoric acid (pyrophosphoric acid)IBA 01/2015
1	Glucagon-Like Peptide-1 ReceptorIBA 06/2011
1	OsteocalcinIBA 08/2007
1	Protein Tyrosine PhosphatasesIBA 08/2007
1	Hypoglycemic Agents (Hypoglycemics)IBA 08/2007
1	Amino Acids FDA Link 12/2006
1	Activating Transcription Factor 4IBA 12/2006
1	Phosphotransferases (Kinase)IBA 12/2006
1	CollagenIBA 12/2006
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2004
1	Transforming Growth Factor beta (TGF-beta)IBA 03/2004
1	Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric 04/2003
1	Alkaline PhosphataseIBA 04/2003
1	LipidsIBA 04/2002
1	LDL CholesterolIBA 04/2002
1	HDL CholesterolIBA 04/2002
1	oxidized low density lipoproteinIBA 04/2002
1	GhrelinIBA 02/2002
1	Insulin (Novolin)FDA Link 02/2002
1	Lymphotoxin-alpha (Lymphotoxin)IBA 01/2002
1	CytokinesIBA 01/2002
1	InterleukinsIBA 01/2002
1	Parathyroid Hormone-Related ProteinIBA 01/2002
1	Interleukin-6 (Interleukin 6)IBA 01/2002

Therapy/Procedure

5	Therapeutics 09/2015 - 06/2011
2	Subcutaneous Injections 11/2014 - 03/2012
2	Glycemic Control 06/2011 - 01/2009
2	Parathyroidectomy 03/2004 - 10/2003
1	Aftercare (After-Treatment) 01/2015